As an outcome of a research programme supported by Wallonia since 2006, DNAlytics was founded in 2012 by Pr P. Dupont and Dr T. Helleputte, from UCL-ICTEAM/INGI.

The spin-off company offers data mining and IT support to the development of diagnostic, prognostic, treatment response prediction solutions from R&D to market access. The setup of such solutions is often coupled with the identification/validation of multi-source marker signatures (genomic, imaging, clinical data, etc.).

The combination of high number of variables and the rather low number of patients available in clinical research is challenging in terms of data analysis, which the technology addresses. DNAlytics is both a service provider for pharma, biotech or In Vitro Diagnostic companies, and a product developer for clinicians. Their technology and business model received many awards (IBM, Microsoft, European Commission, etc.).

Allow 50.000 EU patients/year, suffering from undifferentiated arthritis, benefit from accurate and early diagnosis

DNAlytics: a key player for the world of tomorrow